Caitong International Asset Management’s ImmunityBio IBRX Stock Holding History

Caitong International Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47K	Sell	5,371 -19,654	-79%	-$149K	0.01%	735
2026 Q1	$192K	Buy	25,025 +24,558	+5,259%	+$168K	0.04%	396
2025 Q4	$925	Sell	467 -260	-36%	-$589	﹤0.01%	1383
2025 Q3	$1.79K	Buy	+727	New	+$1.87K	﹤0.01%	1395
2025 Q2	–	Sell	-1,791	Closed	-$5.39K	–	2216
2025 Q1	$5.39K	Sell	1,791 -8,155	-82%	-$24.7K	﹤0.01%	1005
2024 Q4	$25.5K	Buy	+9,946	New	+$41.4K	0.02%	715

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caitong International Asset Management's IBRX Position: Q2 2026 in Review

Caitong International Asset Management reduced its ImmunityBio (IBRX) stake by 79% in Q2 2026, selling an estimated $149K and leaving 5,371 shares worth $47K. The position accounts for 0.01% of the portfolio, ranked #735.

Caitong International Asset Management first reported a position in IBRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $192K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Caitong International Asset Management held 5,371 shares of ImmunityBio worth $47K as of Q2 2026.
Caitong International Asset Management sold 19,654 ImmunityBio shares in Q2 2026, an estimated $149K.
ImmunityBio made up 0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #735 holding.
Caitong International Asset Management first reported a position in ImmunityBio in Q4 2024 and has held it in 6 quarters since.
Caitong International Asset Management's ImmunityBio position peaked at $192K in Q1 2026.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.